The pharmaceutical industry heads into 2026 carrying strong M&A momentum, a surging Chinese deal landscape and continued buzz around obesity drugs and new modalities. Deals involving Chinese pharma and biotech firms reached $92.2 billion in potential value through November 2025. That’s nearly double the $51.9 billion recorded in 2024, according to Mark Lansdell, Director, Asset…
Biotech bounces back at JPM 2024 on optimism, breakthroughs and calculated bets, but uncertainties persist
At the dawn of 2024, there’s a sense of renewed optimism in the biotech sector despite recent sector-specific challenges. This week, the JP Morgan Health Care Conference witnessed strong deal-making activity. For instance, Merck agreed to acquire cancer drug developer Harpoon Therapeutics for roughly $680 million, highlighting continued interest in oncology cancer therapies. Meanwhile, Novartis…